Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
550.20
+4.60
+(0.84%)
At close: February 21 at 5:35:32 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 15 | 15 |
| Avg. Estimate | 745.4M | 767.7M | 3.11B | 3.39B |
| Low Estimate | 729.71M | 762.39M | 3.07B | 3.33B |
| High Estimate | 755M | 772.69M | 3.19B | 3.46B |
| Year Ago Sales | 679.97M | 707.95M | 2.86B | 3.11B |
| Sales Growth (year/est) | 9.62% | 8.44% | 8.79% | 9.03% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 3HM.DE | -- | -- | -- | -- |
| S&P 500 | 14.59% | 7.50% | 10.82% | 14.15% |
Upgrades & Downgrades
| Reiterates | RBC Capital: Outperform to Outperform | 1/30/2025 |
| Maintains | JP Morgan: Overweight to Overweight | 1/30/2025 |
| Maintains | Barclays: Overweight to Overweight | 1/30/2025 |
| Maintains | JP Morgan: Overweight to Overweight | 1/21/2025 |
| Upgrade | Goldman Sachs: Neutral to Buy | 12/18/2024 |
| Maintains | Morgan Stanley: Overweight to Overweight | 12/12/2024 |